Sight Sciences, Inc. (SGHT) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on ...

分组1 - Pacific Biosciences reported a quarterly loss of $0.12 per share, better than the Zacks Consensus Estimate of a loss of $0.19, representing an earnings surprise of +36.84% [1] - The company posted revenues of $44.65 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 9.42%, compared to $39.22 million in the same quarter last year [2] - The stock has underperformed the market, losing about 1.6% since the beginning of the year, while the S&P 500 gained 1.4% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.17 on revenues of $42 million, and for the current fiscal year, it is -$0.57 on revenues of $177.35 million [7] - The Zacks Industry Rank for Medical - Instruments is in the top 34% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

Core Insights - Forian Inc. is facing significant financial challenges with a negative Return on Invested Capital (ROIC) of -13.42% and a ROIC to Weighted Average Cost of Capital (WACC) ratio of -1.52, indicating it is not generating returns above its cost of capital [1][6] Company Performance - Forian Inc. has a ROIC of -13.42% and a WACC of 8.81% [1] - The ROIC to WACC ratio for Forian is -1.52, showing underperformance in generating returns [1][6] Peer Comparison - Ikena Oncology, Inc. has a ROIC of -36.02% and a WACC of 6.18%, resulting in a ROIC to WACC ratio of -5.83 [2] - Finch Therapeutics Group, Inc. reports a ROIC of -38.62% against a WACC of 6.18%, leading to a ratio of -6.25 [2] - NeuroPace, Inc. has a ROIC of -20.32% and a WACC of 12.43%, resulting in a ROIC to WACC ratio of -1.63, indicating it is relatively closer to breaking even [3] - Eledon Pharmaceuticals, Inc. has a ROIC of -75.00% and a WACC of 7.50%, leading to a ROIC to WACC ratio of -10.00 [4] - Werewolf Therapeutics, Inc. reports a ROIC of -87.96% against a WACC of 9.55%, resulting in a ratio of -9.21 [4] Industry Overview - The industry is facing widespread challenges, with all mentioned companies struggling to generate returns that exceed their cost of capital [5][6] - NeuroPace, Inc. shows the most potential for improvement among its peers, with the least negative ROIC to WACC ratio of -1.63 [5][6]

Core Insights - U.S. stocks experienced an upward trend, with the Nasdaq Composite increasing by over 200 points on Wednesday [1] - Johnson Controls International PLC reported fourth-quarter results that exceeded analyst expectations for both earnings and revenue, leading to a significant rise in its stock price [1] Company Performance - Johnson Controls reported adjusted earnings per share of $1.26, surpassing the analyst consensus estimate of $1.20 [1] - The company's quarterly revenue reached $6.44 billion, exceeding the forecast of $6.32 billion [1] - Johnson Controls shares rose by 8% to $119.88 following the earnings report [2] Other Notable Stock Movements - Solid Power Inc saw a 55.7% increase in shares to $8.74 after reporting better-than-expected quarterly EPS results [4] - Babcock & Wilcox Enterprises Inc shares surged by 38.8% to $5.19 due to better-than-expected third-quarter EPS results [4] - Neuropace Inc's shares jumped 38.3% to $13.00 after raising its FY25 sales guidance above estimates [4] - Rigel Pharmaceuticals Inc experienced a 33.8% increase to $37.97 after reporting strong quarterly results and raising FY25 sales guidance [4] - Digital Turbine Inc gained 31.2% to $7.76 after better-than-expected second-quarter results and an increase in FY26 sales guidance [4] - Kennedy-Wilson Holdings Inc rose 31% to $9.79 following a proposal for acquisition at $10.25 per share [4] - Lemonade Inc's shares increased by 30.8% to $76.73 after reporting strong quarterly results and raising FY2025 sales guidance [4] - Teradata Corp gained 25.3% to $26.00 after better-than-expected third-quarter results and an increase in FY25 EPS guidance [4] - Lumentum Holdings Inc's shares rose 23.5% to $232.60 after reporting strong first-quarter results and issuing positive second-quarter guidance [4] - Teva Pharmaceutical Industries Ltd gained 21.5% to $24.85 after beating third-quarter earnings and revenue estimates [4] - Veracyte Inc rose 21.1% to $43.74 after better-than-expected third-quarter results and an increase in FY25 sales guidance [4] - Qualys Inc gained 20.5% to $146.05 after reporting strong quarterly results and raising FY25 guidance [4] - DigitalOcean Holdings Inc's shares increased by 18.6% to $45.99 after better-than-expected third-quarter results and an increase in FY25 sales guidance [4] - Rivian Automotive Inc gained 16.4% to $14.56 after reporting better-than-expected quarterly sales results [4] - Zeta Global Holdings Corp rose 14% to $19.04 after better-than-expected third-quarter results and issuing FY26 sales guidance [4] - Quantumscape Corp gained 13% to $17.47 [4] - Fubotv Inc rose 12.5% to $4.12 [4] - Diebold Nixdorf Inc gained 11.1% to $62.50 following positive earnings [4] - Fluence Energy Inc rose 11% to $21.28 [4] - Seagate Technology Holdings PLC gained 10.8% to $277.59 after announcing exchanges with holders of $500 million principal amount of exchangeable notes [4] - Toast Inc gained 9.3% to $39.00 after reporting better-than-expected quarterly results and receiving an upgraded price target from Morgan Stanley [4] - Marvell Technology Inc gained 6.5% to $93.29 [4]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - SMX (Security Matters) Public Limited Company (SMX) increased by 52% to $2.24 [3] - Entravision Communications Corporation (EVC) rose by 33% to $2.66 [3] - Babcock & Wilcox Enterprises, Inc. (BW) saw a 28% increase to $4.79 [3] - NeuroPace, Inc. (NPCE) gained 24% reaching $11.71 [3] - Kennedy-Wilson Holdings, Inc. (KW) also increased by 24% to $9.30 [3] - Rigel Pharmaceuticals, Inc. (RIGL) rose by 22% to $34.72 [3] - Digital Turbine, Inc. (APPS) increased by 21% to $7.20 [3] - Lumentum Holdings Inc. (LITE) saw a 15% increase to $218.06 [3] - AsiaStrategy (SORA) rose by 14% to $3.63 [3] - Marine Petroleum Trust (MARPS) increased by 7% to $5.05 [3] Premarket Losers - Biohaven Ltd. (BHVN) decreased by 42% to $7.96 [4] - Trex Company, Inc. (TREX) fell by 34% to $30.65 [4] - Soleno Therapeutics, Inc. (SLNO) saw a 23% decline to $49.00 [4] - Axon Enterprise, Inc. (AXON) decreased by 19% to $572.00 [4] - Clover Health Investments, Corp. (CLOV) fell by 19% to $2.82 [4] - Pinterest, Inc. (PINS) decreased by 18% to $26.91 [4] - SSR Mining Inc. (SSRM) saw a 17% decline to $17.91 [4] - Upstart Holdings, Inc. (UPST) decreased by 16% to $38.81 [4] - WF International Limited (WXM) fell by 12% to $2.25 [4] - Corsair Gaming, Inc. (CRSR) decreased by 11% to $6.66 [4]

Core Insights - Several healthcare and biotech companies experienced significant after-hours stock price increases following the release of strong third-quarter earnings and updated guidance for 2025 [1] Company Summaries - **Veracyte Inc. (VCYT)**: - Stock surged 16.07% to $41.92 - Reported third-quarter net income of $19.1 million, a 26% increase year-over-year - Net earnings per share rose to $0.24, up $0.05, while non-GAAP EPS reached $0.51, an increase of $0.18 - Revenue totaled $131.9 million, reflecting 14% growth from $115.9 million in Q3 2024 [2][3] - **Rigel Pharmaceuticals, Inc. (RIGL)**: - Stock jumped 23.33% to $35.00 - Posted third-quarter net income of $27.9 million, more than doubling from $12.4 million last year - Earnings per share came in at $1.46 versus $0.70 last year - Total revenue for the quarter reached $69.5 million [4][5] - **NeuroPace, Inc. (NPCE)**: - Stock rose 16.28% to $10.93 - Reported a narrower net loss of $3.5 million compared to a $5.5 million loss in the same period last year - Revenue grew 30% year-over-year to $27.4 million, up from $21.1 million [6] - **CareDx, Inc. (CDNA)**: - Stock gained 8.47% to $15.75 - Reported GAAP net income of $1.7 million, compared to a $10.6 million loss in the prior-year period - GAAP earnings per share reached $0.03, reversing a $0.20 loss per share last year - Revenue increased 21% to $100.1 million [7][8] - **FibroBiologics, Inc. (FBLG)**: - Stock edged up 5.29% to $0.3443 - Experienced a modest after-hours gain despite a steep decline of over 17% during the regular session - No new financial disclosures were issued alongside the price movement [9]

Group 1: Earnings Performance - Stereotaxis Inc. reported a quarterly loss of $0.05 per share, better than the Zacks Consensus Estimate of a loss of $0.07, representing an earnings surprise of +28.57% [1] - The company posted revenues of $8.8 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 10.67%, compared to revenues of $4.5 million a year ago [2] - Over the last four quarters, Stereotaxis has surpassed consensus EPS estimates just once, but has topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - Stereotaxis shares have lost about 1.3% since the beginning of the year, while the S&P 500 has gained 7.9% [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at -$0.06 for the coming quarter and -$0.25 for the current fiscal year [4][7] - The current Zacks Rank for Stereotaxis is 3 (Hold), indicating expected performance in line with the market in the near future [6] Group 3: Industry Context - The Medical - Instruments industry, to which Stereotaxis belongs, is currently in the bottom 41% of over 250 Zacks industries, which may impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that investors should monitor these revisions closely [5]

Company Performance - PROCEPT BioRobotics Corporation reported a quarterly loss of $0.35 per share, which was better than the Zacks Consensus Estimate of a loss of $0.41, and an improvement from a loss of $0.50 per share a year ago, resulting in an earnings surprise of +14.63% [1] - The company posted revenues of $79.18 million for the quarter ended June 2025, slightly missing the Zacks Consensus Estimate by 0.02%, but showing significant growth from year-ago revenues of $53.35 million [2] - Over the last four quarters, the company has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - PROCEPT BioRobotics shares have declined approximately 40.2% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.35 on revenues of $83.74 million, and for the current fiscal year, it is -$1.49 on revenues of $325.61 million [7] Industry Outlook - The Medical - Instruments industry, to which PROCEPT BioRobotics belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of stocks in this industry can be significantly influenced by the overall industry outlook, with research indicating that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Group 1: Earnings Performance - Orthofix reported quarterly earnings of $0.13 per share, exceeding the Zacks Consensus Estimate of $0.04 per share, and up from $0.05 per share a year ago, representing an earnings surprise of +225.00% [1] - The company posted revenues of $203.12 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.51% and up from $198.62 million year-over-year [2] Group 2: Stock Performance and Outlook - Orthofix shares have declined approximately 37.9% since the beginning of the year, contrasting with the S&P 500's gain of 7.6% [3] - The current consensus EPS estimate for the upcoming quarter is $0.18 on revenues of $200.11 million, and for the current fiscal year, it is $0.49 on revenues of $811.9 million [7] Group 3: Industry Context - The Medical - Instruments industry, to which Orthofix belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment and stock performance [5]

Core Viewpoint - NeuroPace, Inc. expects minimal impact from U.S. tariffs on its operations and financial results, maintaining its gross margin guidance for fiscal year 2025 [1][2]. Group 1: Financial Performance - The company will report its first quarter 2025 financial results on May 13, 2025, with a conference call scheduled for the same day [3]. - NeuroPace anticipates no material impact on gross margin for its DIXI Medical SEEG products, reiterating its gross margin guidance for 2025 [2]. Group 2: Business Operations - NeuroPace manufactures and sells most of its devices in the U.S., with limited supply chain activities outside the country, which contributes to the expected minimal impact from tariffs [2]. - The company has announced the termination of its SEEG distribution agreement with DIXI Medical effective October 1, 2025, followed by a six-month wind-down period [2]. Group 3: Company Overview - NeuroPace is focused on transforming the lives of people with epilepsy through its RNS System, which is the first commercially available brain-responsive platform for personalized treatment [4].